ZEPOSIA® (ozanimod) is a treatment for adults with moderate to severe ulcerative colitis. See safety info and full Prescribing Information.

Dec 30, 2023 · Ozanimod is an oral small molecule therapy that is approved in the USA, the European Union, and other countries as the first sphingosine 1-phosphate receptor modulator for the treatment …

Meeting Summary TNERSHI Ozanimod is an oral medication indicated for the treatment of moderately-to-severely active ulcerative colitis (UC) in adults. This review article summarises the latest data on …

INDICATION ZEPOSIA (ozanimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Information about ozanimod, a treatment for Colitis, one of the two main forms of Inflammatory Bowel Disease (IBD). It includes information on how ozanimod works, how effective it is, possible side …

Sep 22, 2023 · Credit: Getty Images Researchers developed a guide for clinicians to use ozanimod for the treatment of moderate to severe ulcerative colitis. Ulcerative colitis (UC) is a chronic and …

Introduction: Ozanimod (OZA), an oral sphinosine-1-phosphate receptor modulator, has demonstrated efficacy and safety in patients with moderate to severe ulcerative colitis (UC) in clinical trials. We …

Sep 30, 2021 · Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Funded by Bristol Myers Squibb; True …

Jul 28, 2025 · Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation in the colon and rectum, often leading to symptoms such as rectal bleeding, diarrhea, and weight loss. …

Ozanimod - Medication Information What is ozanimod? Ozanimod (brand name: Zeposia®) is a medication used for treating ulcerative colitis that helps block inflammation-causing lymphocytes …